(Reuters) -Novavax beat Wall Street expectations for second-quarter revenue on Wednesday, helped by a $175 million milestone payment related to U.S. approval of its COVID-19 vaccine in May.
The biotech reported total revenue of $239 million, compared with analysts’ average estimate of $147.96 million, according to data compiled by LSEG.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar)
Comments